Publicité
Publicité

ACXP

ACXP logo

Acurx Pharmaceuticals, Inc. Common Stock

2.96
USD
Sponsorisé
+0.04
+1.37%
09 janv., 15:55 UTC -5
Fermé
exchange

Après-marché

2.90

-0.06
-2.20%

ACXP Rapports sur les bénéfices

Ratio de surprise positive

ACXP a dépassé 10 des 15 dernières estimations.

67%

Prochain rapport

Date du prochain rapport
16 mars 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$1.03
Variation implicite de Q3 25 (Revenue/ EPS)
--
/
-16.26%
Variation implicite de Q4 24 (Revenue/ EPS)
--
/
-67.81%

Acurx Pharmaceuticals, Inc. Common Stock earnings per share and revenue

On 12 nov. 2025, ACXP reported earnings of -1.23 USD per share (EPS) for Q3 25, beating the estimate of -1.33 USD, resulting in a 7.95% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -10.75% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 5 analystes forecast an EPS of -1.03 USD, with revenue projected to reach -- USD, implying an baisse of -16.26% EPS, and hausse of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Acurx Pharmaceuticals, Inc. Common Stock reported EPS of -$1.23, beating estimates by 7.95%, and revenue of $0.00, 0% as expectations.
The stock price moved down -10.75%, changed from $5.58 before the earnings release to $4.98 the day after.
The next earning report is scheduled for 16 mars 2026.
Based on 5 analystes, Acurx Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$1.03 and revenue of -- for Q4 2025.
Chèque FXEmpire's Earnings Calendar for today's list of reporting companies.
Publicité